FEIBA 25 U/ml powder and solvent for solution for infusion

Summary of Product Characteristics Updated 17-May-2021 | Takeda UK Ltd

1. Name of the medicinal product

FEIBA 25 U/ml powder and solvent for solution for infusion

2. Qualitative and quantitative composition

Active substance: Factor VIII Inhibitor Bypassing Activity

1 ml contains 25 U* factor VIII inhibitor bypassing activity when reconstituted with 20 ml of Sterilised Water for Injections. FEIBA is presented as powder and solvent to prepare a solution for infusion containing 200 – 600 mg human plasma protein with a Factor Eight Inhibitor Bypassing Activity of 500 U* per vial.

FEIBA contains factors II, IX and X mainly in non-activated form as well as activated factor VII; factor VIII coagulant antigen (FVIII C:Ag) is present in a concentration of up to 0.1 U/l U FEIBA. The factors of the kallikrein-kinin system are present only in trace amounts, if at all.

* 1 unit of FEIBA shortens the activated partial thromboplastin time (aPTT) of a factor VIII inhibitor plasma by 50% of the buffer value (empty value).

Excipients with known effect:

FEIBA contains approximately 80 mg sodium per vial.

For the full list of excipients, see section 6.1.

3. Pharmaceutical form

Powder and solvent for solution for infusion.

The product is presented as a white to off-white or pale green freeze-dried powder or friable solid.

4. Clinical particulars
4.1 Therapeutic indications

• Treatment of spontaneous bleeding and cover of surgical interventions in haemophilia A patients with Factor VIII inhibitors

• Treatment of spontaneous bleeding and cover of surgical interventions in non haemophiliacs with acquired inhibitors to Factor VIII

• Prophylaxis in haemophilia A patients with high-responding inhibitors and frequent joint bleeding

4.2 Posology and method of administration

Treatment should be initiated and supervised by a physician experienced in the management of haemophilia.


The dosage and duration of the therapy is dependent upon the severity of the disorder, the location and extent of the bleeding and the patient's clinical condition.

Dosage and frequency of administration should always be guided by the clinical efficacy in each individual case.

As a general guide a dose of 50 to 100 U of FEIBA per kg body weight (bw) is recommended. A single dose of 100 U/kg body weight and a daily dose of 200 U/kg body weight should not be exceeded unless the severity of bleeding warrants and justifies the use of higher doses. See section 4.4.

The following table can be used to guide dosing in bleeding episodes and surgery.

Therapeutic indication

Dose (U/kg/bw)

Frequency of doses (hours)

Spontaneous Bleeding

Joint muscle and soft tissue haemorrhage

Minor to moderate bleeding

50-75 U/kg/bw

Repeat every 12 hours. Treatment should be continued until clear signs of clinical improvement, such as relief of pain, reduction of swelling or mobilisation of the joint.

Joint muscle and soft tissue haemorrhage

Major bleeding

100 U/kg/bw

Repeat every 12 hours. Treatment should be continued until clear signs of clinical improvement, such as relief of pain, reduction of swelling or mobilisation of the joint.

Mucous membrane bleeding

50 U/kg/bw

if haemorrhage does not stop, the dose may be increased to 100 U/kg/bw

Repeat every 6 hours with careful monitoring of the patient (visible bleeding site, repeated measurements of haematocrit).

Other severe haemorrhage (e.g. CNS)

100 U/kg/bw

Repeat every 12 hours. In individual cases FEIBA may be given at intervals of 6 hours until clear clinical improvement is achieved.



50-100 U/kg/bw

Repeat at intervals of up to 6 hours, then every 8-12 hours until wound healing.

Bleeding prophylaxis

Limited experience has been published on the use of FEIBA in haemophilia A patients with high-responding inhibitors before and during immune tolerance induction (ITI) therapy, or after ITI failure.

For prevention of bleeding episodes during prophylaxis, dose 70 to 100 units per kg body weight every other day. Adjust dose based on the patient's clinical response.

Paediatric population

The experience in children under 6 years of age is limited; the same dose regimen as in adults should be adapted to the child's clinical condition.


• In case of inadequate response to treatment with the product, it is recommended that a platelet count be performed because a sufficient number of functionally intact platelets are considered to be necessary for the efficacy of the product.

• Due to the complex mechanism of action, no direct monitoring of active ingredients is available. Coagulation tests such as whole blood clotting time (WBCT) and the aPTT may not correlate with clinical improvement.

• Global hemostatic tests such as thromboelastogram (TEG) or thrombin generation assay (TGA) may be useful tools to monitor and optimize the treatment.

Method of Administration

Reconstitute the product for administration as described in section 6.6.

FEIBA must be administered as an intravenous injection or infusion. The rate of administration should ensure the comfort of the patient and should not exceed a maximum of 2 U/kg body weight per minute.

4.3 Contraindications

FEIBA must not be used in the following situations if therapeutic alternatives to FEIBA are available:

• Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

• Disseminated intravascular coagulation (DIC)

• Acute thrombosis or embolism (including myocardial infarction)

See section 4.4.

4.4 Special warnings and precautions for use


In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.


Thromboembolic Events

Thromboembolic events, including disseminated intravascular coagulation (DIC), venous thrombosis, pulmonary embolism, myocardial infarction, and stroke, have occurred in the course of treatment with FEIBA.

Some of these events occurred with doses above 200 U/kg/day or in patients with other risk factors (including DIC, advanced atherosclerotic disease, crush injury or septicemia) for thromboembolic events. Concomitant treatment with recombinant Factor VIIa may increase the risk of developing a thromboembolic event. The possible presence of such risk factors should always be considered in patients with congenital and acquired haemophilia.

FEIBA should be used with particular caution in patients at risk of DIC, arterial or venous thrombosis. See Section 4.3.

Thrombotic microangiopathy (TMA) has not been reported in FEIBA clinical studies. Cases of TMAs were reported in an emicizumab clinical trial where subjects received FEIBA as part of a treatment regimen for breakthrough bleeding (see clinical discussion in the European Public Assessment Report (EPAR) of emicizumab; see also Oldenburg et al. Emicizumab Prophylaxis in Hemophilia A with Inhibitors. N Engl J Med 2017:377:809-818). The safety and efficacy of FEIBA for breakthrough bleeding in patients receiving emicizumab has not been established. Consider the benefits and risks if FEIBA must be used in a patient receiving emicizumab prophylaxis.

If treatment with FEIBA is considered required for patients receiving emicizumab, patients must be closely monitored by their physicians.

At the first signs or symptoms of thromboembolic events, the infusion should be stopped immediately and appropriate diagnostic and therapeutic measures initiated.

A single dose of 100 U/kg body weight and a daily dose of 200 U/kg body weight should not be exceeded unless the severity of bleeding warrants and justifies the use of higher doses.

When used to stop bleeding, the product should be given only for as long as absolutely necessary to achieve the therapeutic goal.

Allergic-Type Hypersensitivity Reactions

FEIBA can precipitate allergic-type hypersensitivity reactions that have included, urticaria, angioedema, gastrointestinal manifestations, bronchospasm, and hypotension; these reactions can be severe and can be systemic (e.g., anaphylaxis with urticaria and angioedema, bronchospasm, and circulatory shock). Other infusion reactions, such as chills, pyrexia, and hypertension have also been reported.

At the first sign or symptom of an infusion/hypersensitivity reaction, FEIBA administration should be stopped and medical care initiated as appropriate.

When considering re-exposure to FEIBA in patients with known or suspected hypersensitivity to the product, the expected benefit and the risk of re-exposure must be carefully weighed, taking into account the known or suspected type of the patient's hypersensitivity (allergic or non-allergic), including potential remedial and/or preventative therapy or alternative therapeutic agents.

See section 4.8.

Measures to prevent transmission of infectious agents

Standard measures to prevent infections resulting from the use of medicinal products prepared from human blood or plasma include selection of donors, screening of individual donations and plasma pools for specific markers of infection and the inclusion of effective manufacturing steps for the inactivation/removal of viruses. Despite this, when medicinal products prepared from human blood or plasma are administered, the possibility of transmitting infective agents cannot be totally excluded. This also applies to unknown or emerging viruses and other pathogens.

The measures taken are considered effective for enveloped viruses such as HIV, HBV, and HCV and for the non-enveloped virus HAV. The measures taken may be of limited value against non-enveloped viruses such as parvovirus B19. Parvovirus B19 infection may be serious for pregnant women (foetal infection) and for individuals with immunodeficiency or increased erythropoiesis (e.g. haemolytic anaemia).

Appropriate vaccination (against hepatitis A and B) should be considered for patients in regular/repeated receipt of plasma-derived products including FEIBA.


Discordant Response to Bypassing Agents

Due to patient-specific factors the response to a bypassing agent can vary, and in a given bleeding situation patients experiencing insufficient response to one agent may respond to another agent. In case of insufficient response to one bypassing agent, use of another agent should be considered.

Anamnestic Responses

Administration of FEIBA to patients with inhibitors may result in an initial “anamnestic” rise in inhibitor levels. Upon continued administration of FEIBA, inhibitors may decrease over time.

Interference with Laboratory Tests

After administration of high doses of FEIBA, the transitory rise of passively transferred Hepatitis B surface antibodies may result in misleading interpretation of positive results in serological testing.

FEIBA contains blood group isohemagglutinins (anti-A and anti-B). Passive transmission of antibodies to erythrocyte antigens, e.g., A, B, D, may interfere with some serological tests for red cell antibodies, such as antiglobulin test (Coombs test).

Paediatric population

Case reports and limited clinical trial data suggest that FEIBA can be used in children younger than 6 years of age.


FEIBA contains approximately 80 mg sodium per vial, equivalent to 4% of the WHO recommended maximum daily intake of 2 g sodium for an adult.

4.5 Interaction with other medicinal products and other forms of interaction

No adequate and well-controlled studies of the combined or sequential use of FEIBA and recombinant Factor VIIa, antifibrinolytics, or emicizumab have been conducted.

The possibility of thromboembolic events should be considered when systemic antifibrinolytics such as tranexamic acid and aminocaproic acid are used during treatment with FEIBA. Therefore, antifibrinolytics and FEIBA should be administered at least 6 hours apart.

In cases of concomitant rFVIIa use, according to available in vitro data and clinical observations a potential drug interaction may occur (potentially resulting in adverse events such as a thromboembolic event).

Clinical experience from an emicizumab clinical trial suggests that a potential drug interaction may exist with emicizumab when FEIBA was used as part of a treatment regimen for breakthrough bleeding (see section 4.4).

4.6 Fertility, pregnancy and lactation

There are no adequate data from the use of FEIBA in pregnant or lactating women.

Healthcare providers should balance the potential risks and only prescribe FEIBA if clearly needed, taking into consideration that pregnancy and the postpartum period confer an increased risk of thrombotic events, and several complications of pregnancy that are associated with an increased risk of DIC. Careful medical monitoring is required.

No animal reproduction studies have been conducted with FEIBA.

The effects of FEIBA on fertility have not been established in controlled clinical trials.

See section 4.4 for information on parvovirus B19 infection.

4.7 Effects on ability to drive and use machines

No effects on the ability to drive and use machines have been observed.

4.8 Undesirable effects

The adverse reactions presented in this section have been reported from post-marketing surveillance as well as from 2 studies with FEIBA for the treatment of bleeding episodes in paediatric and adult patients with haemophilia A or B and inhibitors to factors VIII or IX. One study also enrolled acquired haemophilia patients with factor VIII inhibitors (2 of 49 patients).

The adverse reactions presented in the table were reported in the original FEIBA studies (Hilgartner 1983, 2003; Sjamsoedin LJ. et al.,1981) for the treatment of bleeding episodes in haemophilia A or B patients with inhibitors to Factors VIII or IX and the randomized, prospective prophylaxis study (090701) comparing prophylaxis with on-demand treatment.

Frequency categories are defined according to the following convention:

Very common




Very rare

Not known

≥ 1/10

≥ 1/100 to <1/10

≥ 1/1,000 to <1/100

≥ 1/10,000 to <1/1,000

< 1/10,000

cannot be estimated from the available data

System Organ Class (SOC)

Preferred MedDRA Term

Frequency Category*

Blood and lymphatic system disorders

Disseminated intravascular coagulation (DIC)

Increase of inhibitor titre (anamnestic response)*, a

Not known

Immune system disorders



Anaphylactic reaction

Not known

Nervous system disorders




Embolic stroke




Thrombotic stroke

Not known

Cardiac disorders

Cardiac infarction


Not known

Vascular disorders



Arterial thrombosis




Venous thrombosis

Not known

Respiratory, Thoracic, and Mediastinal disorders




Pulmonary embolism


Not known

Gastrointestinal disorders

Abdominal discomfort




Not known

Skin and subcutaneous tissue disorders






Not known

General disorders and administration site conditions

Chest discomfort*

Chest pain*


Feeling hot

Injection site pain



Not known


Hepatitis B surface antibody positive


*A precise estimate of the rate of these adverse reactions is not possible from the available data.

a Increase of inhibitor titre (anamnestic response) [not a MedDRA PT] is the rise of previously existing inhibitor titres occurring after the administration of FEIBA. See Section 4.4.

Class Reactions

Other symptoms of hypersensitivity reactions to plasma-derived products include lethargy and restlessness.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store

4.9 Overdose

Some of the reported thromboembolic events have occurred with doses above 200 U/kg. See section 4.4. If signs or symptoms of thromboembolic events are observed, the infusion should be stopped immediately and appropriate diagnostic and therapeutic measures initiated. See section 4.4.

5. Pharmacological properties
5.1 Pharmacodynamic properties

Pharmacotherapeutic group: activated prothrombin complex against factor VIII antibodies, ATC Code: B02B D03

Although FEIBA was developed in the early 1970s and its factor VIII inhibitor bypassing activity has been demonstrated both in vitro and in vivo, its active principle is still the subject of scientific debate. However, recent scientific work indicates a role of specific components of the activated prothrombin complex, zymogen prothrombin (FII) and activated Factor X (FXa), in the FEIBA mode of action.

Administration of FEIBA to patients with inhibitors may result in an initial “anamnestic” rise in inhibitor levels. Upon continued administration of FEIBA, inhibitors may decrease over time.

Clinical and published data suggest that the efficacy of FEIBA is not reduced.

5.2 Pharmacokinetic properties

Since FEIBA is composed of different coagulation factors, with varying half-lives for the single components, it is not possible to make any definite statement with regard to the pharmacokinetic properties of FEIBA.

5.3 Preclinical safety data

Based on the acute toxicity studies in factor VIII knockout mice and in normal mice and rats with doses exceeding the maximum daily dose in humans (i.e. >200 U/kg bw), it can be concluded that adverse effects related to FEIBA are primarily the result of hypercoagulation induced by the pharmacological properties of the product.

Repeated dose toxicity testing in animals is impracticable due to interference with developing antibodies to heterologous protein.

Since human plasma proteins are not seen to cause tumorigenic or mutagenic effects, experimental studies particularly in heterologous species are not considered necessary.

6. Pharmaceutical particulars
6.1 List of excipients


Sodium Chloride

Sodium Citrate


Water for Injections

6.2 Incompatibilities

No compatibility studies have been performed with the product. Therefore, FEIBA must not be mixed with other medicinal products or solvents.

Coagulation factors derived from human plasma may be adsorbed by the inner surfaces of certain types of injection/infusion devices. If this were to occur, it could result in failure of therapy.

6.3 Shelf life

2 years. The reconstituted solution should be used immediately.

6.4 Special precautions for storage

Do not store above 25°C. Do not freeze.

Keep container in the outer carton in order to protect from light.

6.5 Nature and contents of container

The powder is supplied in a vial made of surface treated, colourless glass (hydrolytic class II). The solvent is supplied in a vial made of surface treated, colourless glass (hydrolytic class I). The vials are closed with butyl rubber stoppers and protective caps.

FEIBA 25 U/ml is available in the following presentation:

Pack size 500 U contains

- 1 vial with 500 U FEIBA powder for solution for infusion

- 1 vial with 20 ml Water for Injections

- 1 BAXJECT II Hi-Flow

6.6 Special precautions for disposal and other handling

- Aseptic conditions are required during preparation of the FEIBA solution and administration.

- The BAXJECT II Hi-Flow is used to reconstitute the powder with the solvent (Water for Injection).

- To prepare the FEIBA solution, use only the solvent and the reconstitution device provided in the pack. For administration the use of a luer lock syringe is recommended.

- FEIBA should be reconstituted just prior to administration. The solution should then be used immediately as the preparation contains no preservatives.

- After reconstitution, the solution should be inspected for particulate matter and discolouration prior to administration. Do not use solutions that are cloudy or have deposits.

- Do not use if the BAXJECT II Hi-Flow device, its sterile barrier system or its packaging is damaged or shows any sign of deterioration.

- Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

Reconstitution of powder: use aseptic technique as described below

1. Warm the FEIBA and solvent vials to room temperature (15°C – 25°C) if necessary.

2. Remove the protective caps from the FEIBA and solvent vials and cleanse the rubber stoppers of both with alcohol swabs. Place the vials on a flat surface.

3. Open the BAXJECT II Hi-Flow device package by peeling away the paper lid without touching the inside (Fig a). Do not remove the device from the package.

4. Turn the package over and insert the clear plastic spike through the solvent stopper (Fig. b). Grip the package at its edge and pull the package off BAXJECT II Hi-Flow (Fig. c). Do not remove the blue cap from BAXJECT II Hi-Flow device.

5. With BAXJECT II Hi-Flow attached to the solvent vial, invert the system so that the solvent vial is on top of the device. Insert the purple plastic spike through the FEIBA stopper. The vacuum will draw the solvent into the FEIBA vial (Fig d).

6. Swirl, but do not shake, the entire system gently until all material is dissolved. Ensure that FEIBA is completely dissolved, otherwise active material will not pass through the device filter.

Figure a

Figure b

Figure c

Instructions for Injection/Infusion:

1. Remove the blue cap from BAXJECT II Hi-Flow. Take the syringe and tightly connect it to BAXJECT II Hi-Flow (DO NOT DRAW AIR INTO THE SYRINGE) (Fig. e). In order to ensure a tight connection between the syringe and BAXJECT II Hi-Flow, the use of a luer lock syringe is highly recommended (turn the syringe in a clockwise direction until the stop position when mounting).

2. Invert the system so that the dissolved product is on top. Draw the FEIBA solution into the syringe by pulling the plunger back SLOWLY and ensure that the tight connection between BAXJECT II Hi-Flow and the syringe is maintained throughout the whole pulling process (Fig. f).

3. Disconnect the syringe.

4. If foaming of the product in the syringe occurs, wait until the foam has collapsed. Slowly administer the solution intravenously with a winged set for injection (or a disposable needle).

Figure d

Figure e

Figure f

If devices other than those supplied with FEIBA are used, ensure use of an adequate filter.

Do not exceed an injection speed of 2 U FEIBA/kg body weight per minute.

7. Marketing authorisation holder

Baxalta Innovations GmbH

Industriestrasse 67

A-1221 Vienna Austria

8. Marketing authorisation number(s)

PL 34078/0002

9. Date of first authorisation/renewal of the authorisation

Date of first authorisation: 17 October 1985

10. Date of revision of the text

14 April 2021

Company Contact Details
Takeda UK Ltd

1 Kingdom Street, London, W2 6BD, UK


+44 3333 000 181

Medical Information e-mail


Medical Information Direct Line

+44 (0)3333 000 181

Drug Safety e-mail